Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013

Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference

Peregrine Pharmaceuticals to Present at Upcoming Conferences

Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments

Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2013 Financial Results After Market Close on July 11, 2013

Peregrine Pharmaceuticals Provides Update on Bavituximab Clinical Program

Peregrine Pharmaceuticals to Join Russell 3000 and Russell Global Indexes

Encouraging Results in Breast and Pancreatic Cancers for Patients Treated With Peregrine's Novel Immunotherapy Bavituximab Presented at ASCO

Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab

Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer